Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT02013219 trial: what clinicians have said so far
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
- NCT02013219 ↗
- Completed
- Hoffmann-La Roche
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT02013219 (atezolizumab plus erlotinib; atezolizumab plus alectinib in advanced non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02013219 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Alectinib; Atezolizumab; Erlotinib
- Arms
- Stage 1: Alectinib and Atezolizumab · Experimental
- Stage 1: Erlotinib and Atezolizumab · Experimental
- Stage 2: Alectinib and Atezolizumab · Experimental
- Stage 2: Erlotinib and Atezolizumab · Experimental
- Enrollment
- 52
- Primary outcomes
- Percentage of Participants with Dose-Limiting Toxicities (DLTs)
- Recommended Phase II Dose (RP2D) of Atezolizumab and Erlotinib
- Recommended RP2D of Atezolizumab and Alectinib
- Sponsor
- Hoffmann-La Roche
- Start
- Apr 3, 2014
- Primary completion
- Feb 5, 2020
- Results posted
- No
- Registry record
- NCT02013219 · updated Apr 21, 2020